StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.
Separately, Cantor Fitzgerald reiterated a neutral rating and issued a $3.30 target price on shares of Aspira Women’s Health in a research report on Wednesday, April 10th.
View Our Latest Research Report on Aspira Women’s Health
Aspira Women’s Health Stock Up 13.7 %
Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last announced its earnings results on Tuesday, May 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $2.10 million. Aspira Women’s Health had a negative net margin of 163.95% and a negative return on equity of 1,099.32%. During the same quarter in the prior year, the company earned ($10.94) EPS. Equities analysts forecast that Aspira Women’s Health will post -1.3 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of AWH. B. Riley Wealth Advisors Inc. raised its holdings in shares of Aspira Women’s Health by 43.1% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock valued at $732,000 after purchasing an additional 53,997 shares in the last quarter. Northeast Financial Consultants Inc bought a new position in shares of Aspira Women’s Health during the 3rd quarter valued at $126,000. Finally, Quantum Private Wealth LLC raised its holdings in shares of Aspira Women’s Health by 76.8% during the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after purchasing an additional 21,788 shares in the last quarter. Institutional investors own 12.19% of the company’s stock.
About Aspira Women’s Health
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
Featured Stories
- Five stocks we like better than Aspira Women’s Health
- Golden Cross Stocks: Pattern, Examples and Charts
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- The How and Why of Investing in Gold Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.